Could a daily pill shield frontline workers from COVID?
NCT ID NCT04405271
Summary
This study tested whether a daily pill (Emtricitabine/Tenofovir) could prevent COVID-19 in healthcare workers at high risk of exposure. Over 1,300 participants were randomly assigned to receive either the pill or a placebo, in addition to standard safety measures like masks. The main goal was to see if the pill reduced the number of new COVID-19 cases over 12 weeks.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sociedad Argentina de Infectología, A. J. Carranza 974
Buenos Aires, Buenos Aires F.D., C1085, Argentina
Conditions
Explore the condition pages connected to this study.